Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Context Therapeutics Inc. (CNTX) SEC filings page on Stock Titan provides access to the company’s public regulatory documents, including current reports on Form 8-K and other filings made with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Context describes its business as a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors, along with information on its capital markets activity and Nasdaq listing status.
Recent Forms 8-K furnished by Context include clinical and corporate updates tied to its TCE pipeline. For example, the company has reported Phase 1 dose-escalation progress for CTIM-76, a Claudin 6 x CD3 TCE in patients with ovarian, endometrial, or testicular cancer, and CT-95, a Mesothelin x CD3 TCE in patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers. Filings also describe CT-202, a Nectin-4 x CD3 TCE in preclinical development, and summarize safety observations, preliminary anti-tumor activity, and planned next steps as of the filing dates.
Other 8-Ks detail capital raising arrangements, such as an at-the-market Sales Agreement and its amendment, including aggregate offering limits, use of proceeds for research and development, working capital, and general corporate purposes, and the agent’s commission structure. Additional filings address Nasdaq minimum bid price notifications, extensions, and the company’s subsequent return to compliance, which are relevant for understanding listing risk and trading status.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, financing terms, and listing-related updates. Users can review new CNTX filings as they appear in EDGAR, then rely on AI-generated overviews to navigate complex regulatory language and focus on the sections most relevant to their analysis.
Context Therapeutics Inc. furnished an updated corporate presentation dated January 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is provided as Exhibit 99.1 to this report and is incorporated by reference for informational purposes. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished, not filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.
Context Therapeutics (CNTX) announced pipeline updates alongside its third-quarter 2025 communication. The company highlighted progress in three bispecific T cell engager programs across early development.
CTIM-76 (CLDN6 x CD3) Phase 1: 12 patients enrolled as of October 30, 2025; currently in Cohort 5 with a 140 mcg priming dose and 560 mcg full dose. Preliminary signs of anti-tumor activity, including an ongoing RECIST response, were observed beginning at Cohort 3. No CRS greater than Grade 1, no dose-limiting toxicities, and the maximum tolerated dose has not been reached. The company plans updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026.
CT-95 (MSLN x CD3) Phase 1: 6 patients enrolled; in Cohort 3 with a 0.18 µg/kg priming dose and 0.6 µg/kg full dose. Based on preclinical work, target dose exposure is projected starting at Cohort 4. No CRS greater than Grade 2, no DLTs, and no MTD reached. Initial Phase 1a data are anticipated mid‑2026.
CT-202 (Nectin‑4 x CD3): preclinical program expects regulatory filings to support a first‑in‑human trial in the second quarter of 2026.
Context Therapeutics (CNTX) reported Q3 2025 results showing continued investment in its T‑cell engager pipeline and a narrower quarterly loss. Net loss was $9,693,237 versus $17,459,893 a year ago, as research and development declined year over year. Cash and cash equivalents were $76,938,183 as of September 30, 2025, supporting operations the company indicates extend into 2027.
R&D expense was $8,722,104, driven by CT‑202 manufacturing and preclinical work and ongoing trials for CTIM‑76 and CT‑95; general and administrative was $1,888,376. The company dosed first patients in CTIM‑76 (January 2025) and CT‑95 (April 2025) Phase 1 studies and plans to share initial readouts in 2026. In October 2025, CNTX achieved a $2,000,000 development milestone under the BioAtla agreement, and on November 3, 2025, it entered a CT‑202 license with Lonza covering manufacturing IP.
Capital resources include an amended at‑the‑market facility filed on October 24, 2025 permitting sales of up to $75,000,000 of common stock (exclusive of shares sold in 2024). Shares outstanding were 91,879,177 as of November 4, 2025.
Context Therapeutics Inc. amended its at-the-market equity program with Leerink Partners, allowing the company to offer and sell common stock with an aggregate offering price of up to $75.0 million as of October 24, 2025, exclusive of shares previously sold under its prior ATM prospectus.
Under the prior ATM prospectus dated December 2, 2024, the company sold 14,705,882 shares for an aggregate offering price of approximately $15.0 million. The amended program will use the company’s Form S-3 (File No. 333-283037), declared effective on November 14, 2024, as supplemented on October 24, 2025.
Leerink Partners will receive a commission of up to 3.0% of gross proceeds. Context plans to use any net proceeds for research and development, working capital, and general corporate purposes, which may include asset acquisitions. The company also suspended and terminated the prior ATM sales prospectus.
Context Therapeutics (CNTX) launched an at‑the‑market offering of up to $75,000,000 of common stock under an amended Sales Agreement with Leerink Partners. Shares may be sold from time to time on Nasdaq or other markets as defined in Rule 415(a)(4), with Leerink acting as sales agent on commercially reasonable efforts terms.
The company will receive the proceeds from any sales and expects to use them for research and development, working capital and general corporate purposes, which may include acquiring additional assets. Leerink Partners will earn up to 3.0% of aggregate gross proceeds as compensation. From December 2024 through October 2025, the company previously sold 14,705,882 shares under the program for $15.0 million gross and $14.5 million net.
CNTX’s common stock trades on Nasdaq under “CNTX”; the last reported price was $1.21 per share on October 22, 2025. The filing highlights potential dilution and pricing variability typical of ATM programs.
Context Therapeutics reported that it has regained compliance with Nasdaq’s Minimum Bid Price Rule. Nasdaq notified the company on October 17, 2025 that the closing bid price of CNTX common stock has been at $1.00 per share or greater for the last 10 consecutive business days, and that the matter is closed.
The company previously received deficiency notices and an extension to regain compliance until February 23, 2026. This update confirms CNTX remains listed on Nasdaq under the rule.
Context Therapeutics Inc. reported that Nasdaq has granted the company an additional 180 days, until February 23, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This follows an earlier notice received on February 27, 2025, that the company’s stock had traded below the $1.00 minimum closing bid price for 30 consecutive business days.
The new extension does not immediately affect the listing or trading of the company’s common stock on Nasdaq. Context Therapeutics plans to monitor its share price and is evaluating options to regain compliance, including a potential reverse stock split, but it notes there is no assurance it will meet the requirement by the extended deadline.
Context Therapeutics Inc. Schedule 13G/A discloses that Great Point Partners, LLC and two principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, report shared beneficial ownership of 4,683,711 shares of Context Therapeutics common stock, representing 5.22% of the outstanding class based on 89,704,194 shares outstanding. The filing states Great Point is investment manager to two record holders (BVF and BOVF) whose holdings are included in the aggregate, while the reporting parties disclaim beneficial ownership except to the extent of pecuniary interests. The report is filed jointly under a dated joint filing agreement and affirms the holdings were not acquired to influence control.
Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.
The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
